Daratumumab is under clinical development by Johnson & Johnson and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Daratumumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daratumumab overview
Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex, Dalinvi, Darzalex Faspro) is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody against CD38 antigen, produced in a mammalian cell line. It is formulated as solution and concentrate solution for intravenous route of administration. Daratumumab is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent. Darzalex is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy, and in combination with bortezomib, melphalan and prednisone (VMP), for the treatment of patients newly diagnosed with multiple myeloma who are ineligible for autologous stem cell transplantation, in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant, and in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). It is also indicated in combination with carfilzomib and dexamethasone (DKd) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy and also indicated in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
Daratumumab is under development for treatment of precursor B-cell lymphoblastic leukemia-lymphoma, T-cell leukemia, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), relapsed or refractory plasmablastic lymphoma, POEMS syndrome, metastatic renal cell carcinoma or muscle invasive bladder cancer, plasma cell leukemia, pancreatic adenocarcinnoma rheumatoid arthritis, chronic lymphocytic leukemia, amyloid light-chain (AL) amyloidosis (primary systemic amyloidosis) as a first line therapy, front line multiple myeloma, T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma relapsed and refractory natural killer/T-cell lymphomas (NKTCL) and acute lymphoblastic leukemia, systemic lupus erythematosus, lupus nephritis, primary antiphospholipid syndrome and pancreatic ductal adenocarcinoma. It is developed using recombinant DNA technology. It is a new molecular entity (NME). It was also under development for the treatment of triple negative breast cancer, pancreatic cancer, relapsed or refractory B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, prostate cancer as first-line therapy, non-small cell lung cancer, waldenstrom macroglobulinemia and relapsed or refractory acute myelogenous leukemia, myelodysplastic syndrome.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products and medical devices. The company conducts business through its operating companies. It provides pharmaceuticals for immune disorders, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; and medical devices for use in cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, healthcare professionals and hospitals. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US) and Latin America. J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of Daratumumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
